Rupesh Sanjaykumar Jain

Mr. Rupesh Sanjaykumar Jain

Pharmacy, Birla Institute of Technology and Science, Pilani, Pilāni, India
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
SMShambo Mohanty
Shambo Mohanty
VDVaibhavi Meghraj Desai
Vaibhavi Meghraj Desai
RJRupesh Sanjaykumar Jain
Rupesh Sanjaykumar Jain
MAMukta Agrawal
Mukta Agrawal
SDSunil Dubey
Sunil Dubey
GSGautam Singhvi
Gautam Singhvi
Skin carcinoma is one of the most prevalent types of carcinomas. Due to high incidence of side effects in conventional therapies (radiotherapy and chemotherapy), photodynamic therapy (PDT) has gained huge attention as an alternate treatment strategy. PDT involves the administration of photosensitizers (PS) to carcinoma cells which produce reactive oxygen species (ROS) on irradiation by specific wavelengths of light that result in cancer cells' death via apoptosis, autophagy, or necrosis. Topical delivery of PS to the skin cancer cells at the required concentration is a challenge due to the compounds' innate physicochemical characteristics. Nanocarriers have been observed to improve skin permeability and enhance the therapeutic efficiency of PDT. Polymeric nanoparticles (NPs), metallic NPs, and lipid nanocarriers have been reported to carry PS successfully with minimal side effects and high effectiveness in both melanoma and non-melanoma skin cancers. Advanced carriers such as quantum dots, microneedles, and cubosomes have also been addressed with reported studies to show their scope of use in PDT-assisted skin cancer treatment. In this review, nanocarrier-aided PDT in skin cancer therapies has been discussed with clinical trials and patents. Additionally, novel nanocarriers that are being investigated in PDT are also covered with their future prospects in skin carcinoma treatment.

23 October 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
RJRupesh Sanjaykumar Jain
Rupesh Sanjaykumar Jain
ISIla Sarode
Ila Sarode
GSGautam Singhvi
Gautam Singhvi
SDSunil Dubey
Sunil Dubey
Skin cancers are one of the most widespread and complex forms of the disease, resulting in very high mortality rates across the world. The current treatments available for skin cancer include chemotherapy, surgery, radiotherapy, etc. The selected treatment options for skin cancer are usually decided based on the condition of a patient and the type of skin cancer. The effectiveness of skin cancer therapy is still limited because of poor penetrability of the drug into stratum corneum or lesions, low efficacy, required higher concentration of the active pharmaceutical ingredients to reach a therapeutic effect. Besides, low bioavailability at the site of action, the requirement of high dose, causes skin irritation, which significantly hinders the drug absorption through the stratum corneum. Thus, nanocarriers have been used to bypass the problems associated with conventional anti-cancer drug delivery systems. In the current scenario, nanotechnology-based therapy has shown great potential in the management of skin cancer, and these can be used for a more efficient drug delivery system to treat cancers. In this review article, the information on different nanocarrier systems for skin cancer has been elucidated. Moreover, the various nanoparticulate strategies and their effectiveness to treat skin cancer have been discussed.

28 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RJRupesh Sanjaykumar Jain
Rupesh Sanjaykumar Jain
SMShambo Mohanty
Shambo Mohanty
ISIla Sarode
Ila Sarode
SBSwati Biswas
Swati Biswas
GSGautam Singhvi
Gautam Singhvi
SDSunil Dubey
Sunil Dubey
Numerous treatments are available for cancer, including chemotherapy, immunotherapy, radiation therapy, hormone therapy, biomarker testing, surgery, photodynamic therapy, etc. Photodynamic therapy (PDT) is an effective, non-invasive, novel, and clinically approved strategy to treat cancer. In PDT, three main agents are utilized, i.e., photosensitizer (PS) drug, oxygen, and light. At first, the photosensitizer is injected into blood circulation or applied topically, where it quickly becomes absorbed or accumulated at the tumor site passively or actively. Afterward, the tumor is irradiated with light which leads to the activation of the photosensitizing molecule. PS produces the reactive oxygen species (ROS), resulting in the death of the tumor cell. However, the effectiveness of PDT for tumor destruction is mainly dependent on the cellular uptake and water solubility of photosensitizer molecules. Therefore, the delivery of photosensitizer molecules to the tumor cell is essential in PDT against cancer. The non-specific distribution of photosensitizer results in unwanted side effects and unsuccessful therapeutic outcomes. Therefore, to improve PDT clinical outcomes, the current research is mostly focused on developing actively targeted photosensitizer molecules, which provide a high cellular uptake and high absorption capacity to the tumor site by overcoming the problem associated with conventional PDT. Therefore, this review aims to provide current knowledge on various types of actively and passively targeted organic and inorganic nanocarriers for different cancers.